{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+placebo+in+prefilled+syringe&page=2", "query": { "intervention": "Matching placebo in prefilled syringe", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+placebo+in+prefilled+syringe&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+placebo+in+prefilled+syringe&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T22:40:56.575Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04157348", "title": "Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Granulomatous Vasculitis" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Mepolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo to Mepolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo to Benralizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 140, "start_date": "2019-10-29", "completion_date": "2026-11-30", "has_results": true, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 9, "location_summary": "Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Great Neck", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157348" }, { "nct_id": "NCT03953300", "title": "Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 75, "start_date": "2019-10-08", "completion_date": "2026-10-19", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Snellville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03953300" }, { "nct_id": "NCT02443298", "title": "Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 214, "start_date": "2015-06-23", "completion_date": "2018-02-02", "has_results": true, "last_update_posted_date": "2019-04-10", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 20, "location_summary": "Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443298" }, { "nct_id": "NCT06940141", "title": "Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma Acute" ], "interventions": [ { "name": "Rademikibart in prefilled syringe", "type": "COMBINATION_PRODUCT" }, { "name": "Matching placebo in prefilled syringe", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Connect Biopharm LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 160, "start_date": "2025-08-08", "completion_date": "2026-08-10", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 21, "location_summary": "Palo Alto, California • Valencia, California • Wilmington, Delaware + 17 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Valencia", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06940141" }, { "nct_id": "NCT06834360", "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray (MFNS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2025-02-06", "completion_date": "2027-10-11", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 15, "location_summary": "Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834360" }, { "nct_id": "NCT01920477", "title": "Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus Vulgaris" ], "interventions": [ { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2013-08-13", "completion_date": "2018-01-11", "has_results": true, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 7, "location_summary": "Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920477" }, { "nct_id": "NCT00385736", "title": "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 576, "start_date": "2006-11", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-04-11", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00385736" }, { "nct_id": "NCT03385564", "title": "An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "BI 655064", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 69, "start_date": "2018-01-09", "completion_date": "2021-07-27", "has_results": true, "last_update_posted_date": "2022-07-13", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 4, "location_summary": "Plantation, Florida • Great Neck, New York • Manhasset, New York + 1 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Great Neck", "state": "New York" }, { "city": "Manhasset", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03385564" }, { "nct_id": "NCT07190209", "title": "Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Lunsekimig", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 942, "start_date": "2025-09-16", "completion_date": "2030-01-22", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 73, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 60 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "La Palma", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190209" }, { "nct_id": "NCT02683746", "title": "Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lyophilized albiglutide DCC pen injector", "type": "DRUG" }, { "name": "Lyophilized albiglutide DCC pen injector matching placebo", "type": "DRUG" }, { "name": "Albiglutide liquid auto-injector", "type": "DRUG" }, { "name": "Albiglutide liquid auto-injector matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 308, "start_date": "2016-03-16", "completion_date": "2017-05-15", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-10T22:40:56.575Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02683746" } ] }